Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007

Fig. 3

Maximum intensity projections (MIP) of micro PET scans. Summation image (60–90 min p.i.; 0% to 20% IA/mL) of LNCaP-tumor-bearing SCID mice after injection of approximately 0.9–1 MBq of a 18F-DCFPyl; b 18F-PSMA-1007; c left: EuE-k-18F-FBOA, right: EuE-k-18F-FBOA + blocking with 8 mg/kg PMPA; d left: EuE-k-β-a-18F-FPyl, EuE-k-β-a-18F-FPyl + blocking with 8 mg/kg (PMPA). LNCaP tumors are indicated with arrows (please note that the animal shown in panel c bears LNCaP tumors at the right shoulder and on the flank of the hind leg). Organs are marked as B = bladder, GB = gallbladder, K = kidney, L = liver

Back to article page